The Experts below are selected from a list of 46275 Experts worldwide ranked by ideXlab platform
Jiyeon Lee - One of the best experts on this subject based on the ideXlab platform.
-
Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)—a randomized controlled trial
Supportive Care in Cancer, 2019Co-Authors: Sun Young Rha, Jung Mo Nam, Jiyeon LeeAbstract:PurposeTo develop a Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE) and evaluate the effect and feasibility of the system in cancer Symptom Management.MethodsThe Cancer Symptom Management System: SMILE was developed, and a nonblinded, randomized controlled trial was conducted. Cancer patients starting adjuvant or palliative chemotherapy (CTx) were enrolled and randomized to control (Symptom monitoring), experimental 1 (Exp 1; Symptom monitoring + report), or experimental 2 (Exp 2; Symptom monitoring + report + Oncology Nursing Society putting evidence into practice (ONS PEP)–guided evidence-based Symptom Management education) groups in a 1:2:2 ratio ( N = 249). To evaluate whether Symptom Management education provided additional benefit to continuous Symptom monitoring, the Exp 1 and Exp 2 groups were compared utilizing Mann-Whitney U test and generalized estimating equations ( n = 199).ResultsSymptom severity (Symptom total score) at each measurement point was not different among the three groups ( p > .05). Fatigue and sleep disturbance changes were different between Exp 1 and Exp 2 among patients receiving adjuvant CTx ( p = .042 and p = .008). Fatigue gradually decreased after a peak at the 1st CTx cycle in Exp 2, whereas Exp 1 experienced increasing fatigue until the 3rd CTx cycle. A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the Symptom. Participants were willing to participate in Symptom monitoring using the cancer Symptom Management system. Symptom Management education was easy to follow and helpful.ConclusionThe application of the Cancer Symptom Management System: SMILE incorporating ONS PEP–guided evidence-based Symptom Management education effectively managed fatigue and sleep disturbance after adjuvant CTx. The feasibility of the system has been demonstrated. Incorporating the system into electronic medical systems and integrating provider input will be necessary.
-
Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019Co-Authors: Sun Young Rha, Jung Mo Nam, Jiyeon LeeAbstract:To develop a Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE) and evaluate the effect and feasibility of the system in cancer Symptom Management. The Cancer Symptom Management System: SMILE was developed, and a nonblinded, randomized controlled trial was conducted. Cancer patients starting adjuvant or palliative chemotherapy (CTx) were enrolled and randomized to control (Symptom monitoring), experimental 1 (Exp 1; Symptom monitoring + report), or experimental 2 (Exp 2; Symptom monitoring + report + Oncology Nursing Society putting evidence into practice (ONS PEP)–guided evidence-based Symptom Management education) groups in a 1:2:2 ratio (N = 249). To evaluate whether Symptom Management education provided additional benefit to continuous Symptom monitoring, the Exp 1 and Exp 2 groups were compared utilizing Mann-Whitney U test and generalized estimating equations (n = 199). Symptom severity (Symptom total score) at each measurement point was not different among the three groups (p > .05). Fatigue and sleep disturbance changes were different between Exp 1 and Exp 2 among patients receiving adjuvant CTx (p = .042 and p = .008). Fatigue gradually decreased after a peak at the 1st CTx cycle in Exp 2, whereas Exp 1 experienced increasing fatigue until the 3rd CTx cycle. A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the Symptom. Participants were willing to participate in Symptom monitoring using the cancer Symptom Management system. Symptom Management education was easy to follow and helpful. The application of the Cancer Symptom Management System: SMILE incorporating ONS PEP–guided evidence-based Symptom Management education effectively managed fatigue and sleep disturbance after adjuvant CTx. The feasibility of the system has been demonstrated. Incorporating the system into electronic medical systems and integrating provider input will be necessary.
Margaret M. Byrne - One of the best experts on this subject based on the ideXlab platform.
-
Factors related to menopausal Symptom Management decisions
Maturitas, 2011Co-Authors: Janet S. Carpenter, Margaret M. Byrne, Jamie L. StudtsAbstract:Abstract Objective To systematically review the literature regarding factors related to women's menopausal Symptom Management decision making. Methods The PubMed.gov online search engine was queried using pre-selected inclusion and exclusion criteria. Reference lists of articles were also reviewed to identify potentially missed articles. Full-text, English-language, peer-reviewed articles on factors related to menopausal Symptom Management decisions were reviewed. Results A total of 16 articles (15 data-based, 1 review of literature) from 6 different countries were reviewed. Most articles were related to decisions about one class of therapies and did not take into account all available therapeutic options. In the 15 data-based articles, diverse methods were used: qualitative (47%), quantitative (47%), and mixed (6%), with most being cross-sectional (93%). Very few of the data-based articles were based on a conceptual model (20%) and none used findings to derive an explanatory or predictive model. Most samples were not representative of special populations, such as women with breast cancer. Factors fell into four broad categories: (1) individual characteristics (demographics, menopause experience, Symptomatology); (2) values, attitudes, beliefs, and preferences (attitudes and beliefs about menopause and treatments, preferred modalities, tolerance for risks/side effects); (3) facts and information about menopause and Symptom Management (amount, type, source, credibility, availability); and (4) health care context (health care provider communication, trust, availability/time, knowledge, relationship). Conclusions Additional descriptive studies are needed understand women's menopausal Symptom Management decisions in the context of all available therapies so that a comprehensive model of menopausal Symptom Management decision making can be specified. Additional understanding is needed regarding decisions in special populations of menopausal women such as breast cancer survivors, a group for whom menopausal Symptom Management can be particularly complex.
-
a systematic review of menopausal Symptom Management decision aid trials
Maturitas, 2011Co-Authors: Janet S. Carpenter, Jamie L. Studts, Margaret M. ByrneAbstract:Abstract Objective To systematically review the literature regarding the effects of menopausal Symptom Management decision aids. Methods Using pre-designated inclusion and exclusion criteria, relevant articles were located using the PubMed.gov online search engine and reviewing reference lists of relevant articles. Full-text, English-language, peer-reviewed articles relevant to testing decision aids in uncontrolled trials (UCT) and randomized controlled trials (RCT) were reviewed. Results The 18 articles represented 15 trials focused on natural health products decision aids (1 UCT, 1 RCT) or hormone therapy decision aids (1 UCT, 12 RCT). Whereas the natural health products aid was intended for women deciding about menopausal Symptom Management strategies, decision aids for hormone therapy were intended for a broader group of menopausal women and included indications for Symptom Management, prevention of heart disease, and prevention of osteoporosis. Many trials occurred prior to two pivotal events: the 2002 announcement of the Women's Health Initiative findings and the 2006 publication of the International Patient Decision Aids Standards. Study limitations may help explain contradictory findings for outcomes such as decisional conflict, decisional confidence, decisional satisfaction, knowledge and values, and decisions. Conclusions There is a relatively scant contemporary literature related to menopausal Symptom Management decision aids. Additional methodologically sound studies are needed to develop and subsequently test decision aids that are based on (a) contemporary knowledge regarding the wide array of available therapies and (b) international standards for decision aids that include consideration of women's values and preferences.
Janet S. Carpenter - One of the best experts on this subject based on the ideXlab platform.
-
Factors related to menopausal Symptom Management decisions
Maturitas, 2011Co-Authors: Janet S. Carpenter, Margaret M. Byrne, Jamie L. StudtsAbstract:Abstract Objective To systematically review the literature regarding factors related to women's menopausal Symptom Management decision making. Methods The PubMed.gov online search engine was queried using pre-selected inclusion and exclusion criteria. Reference lists of articles were also reviewed to identify potentially missed articles. Full-text, English-language, peer-reviewed articles on factors related to menopausal Symptom Management decisions were reviewed. Results A total of 16 articles (15 data-based, 1 review of literature) from 6 different countries were reviewed. Most articles were related to decisions about one class of therapies and did not take into account all available therapeutic options. In the 15 data-based articles, diverse methods were used: qualitative (47%), quantitative (47%), and mixed (6%), with most being cross-sectional (93%). Very few of the data-based articles were based on a conceptual model (20%) and none used findings to derive an explanatory or predictive model. Most samples were not representative of special populations, such as women with breast cancer. Factors fell into four broad categories: (1) individual characteristics (demographics, menopause experience, Symptomatology); (2) values, attitudes, beliefs, and preferences (attitudes and beliefs about menopause and treatments, preferred modalities, tolerance for risks/side effects); (3) facts and information about menopause and Symptom Management (amount, type, source, credibility, availability); and (4) health care context (health care provider communication, trust, availability/time, knowledge, relationship). Conclusions Additional descriptive studies are needed understand women's menopausal Symptom Management decisions in the context of all available therapies so that a comprehensive model of menopausal Symptom Management decision making can be specified. Additional understanding is needed regarding decisions in special populations of menopausal women such as breast cancer survivors, a group for whom menopausal Symptom Management can be particularly complex.
-
a systematic review of menopausal Symptom Management decision aid trials
Maturitas, 2011Co-Authors: Janet S. Carpenter, Jamie L. Studts, Margaret M. ByrneAbstract:Abstract Objective To systematically review the literature regarding the effects of menopausal Symptom Management decision aids. Methods Using pre-designated inclusion and exclusion criteria, relevant articles were located using the PubMed.gov online search engine and reviewing reference lists of relevant articles. Full-text, English-language, peer-reviewed articles relevant to testing decision aids in uncontrolled trials (UCT) and randomized controlled trials (RCT) were reviewed. Results The 18 articles represented 15 trials focused on natural health products decision aids (1 UCT, 1 RCT) or hormone therapy decision aids (1 UCT, 12 RCT). Whereas the natural health products aid was intended for women deciding about menopausal Symptom Management strategies, decision aids for hormone therapy were intended for a broader group of menopausal women and included indications for Symptom Management, prevention of heart disease, and prevention of osteoporosis. Many trials occurred prior to two pivotal events: the 2002 announcement of the Women's Health Initiative findings and the 2006 publication of the International Patient Decision Aids Standards. Study limitations may help explain contradictory findings for outcomes such as decisional conflict, decisional confidence, decisional satisfaction, knowledge and values, and decisions. Conclusions There is a relatively scant contemporary literature related to menopausal Symptom Management decision aids. Additional methodologically sound studies are needed to develop and subsequently test decision aids that are based on (a) contemporary knowledge regarding the wide array of available therapies and (b) international standards for decision aids that include consideration of women's values and preferences.
Jamie L. Studts - One of the best experts on this subject based on the ideXlab platform.
-
Factors related to menopausal Symptom Management decisions
Maturitas, 2011Co-Authors: Janet S. Carpenter, Margaret M. Byrne, Jamie L. StudtsAbstract:Abstract Objective To systematically review the literature regarding factors related to women's menopausal Symptom Management decision making. Methods The PubMed.gov online search engine was queried using pre-selected inclusion and exclusion criteria. Reference lists of articles were also reviewed to identify potentially missed articles. Full-text, English-language, peer-reviewed articles on factors related to menopausal Symptom Management decisions were reviewed. Results A total of 16 articles (15 data-based, 1 review of literature) from 6 different countries were reviewed. Most articles were related to decisions about one class of therapies and did not take into account all available therapeutic options. In the 15 data-based articles, diverse methods were used: qualitative (47%), quantitative (47%), and mixed (6%), with most being cross-sectional (93%). Very few of the data-based articles were based on a conceptual model (20%) and none used findings to derive an explanatory or predictive model. Most samples were not representative of special populations, such as women with breast cancer. Factors fell into four broad categories: (1) individual characteristics (demographics, menopause experience, Symptomatology); (2) values, attitudes, beliefs, and preferences (attitudes and beliefs about menopause and treatments, preferred modalities, tolerance for risks/side effects); (3) facts and information about menopause and Symptom Management (amount, type, source, credibility, availability); and (4) health care context (health care provider communication, trust, availability/time, knowledge, relationship). Conclusions Additional descriptive studies are needed understand women's menopausal Symptom Management decisions in the context of all available therapies so that a comprehensive model of menopausal Symptom Management decision making can be specified. Additional understanding is needed regarding decisions in special populations of menopausal women such as breast cancer survivors, a group for whom menopausal Symptom Management can be particularly complex.
-
a systematic review of menopausal Symptom Management decision aid trials
Maturitas, 2011Co-Authors: Janet S. Carpenter, Jamie L. Studts, Margaret M. ByrneAbstract:Abstract Objective To systematically review the literature regarding the effects of menopausal Symptom Management decision aids. Methods Using pre-designated inclusion and exclusion criteria, relevant articles were located using the PubMed.gov online search engine and reviewing reference lists of relevant articles. Full-text, English-language, peer-reviewed articles relevant to testing decision aids in uncontrolled trials (UCT) and randomized controlled trials (RCT) were reviewed. Results The 18 articles represented 15 trials focused on natural health products decision aids (1 UCT, 1 RCT) or hormone therapy decision aids (1 UCT, 12 RCT). Whereas the natural health products aid was intended for women deciding about menopausal Symptom Management strategies, decision aids for hormone therapy were intended for a broader group of menopausal women and included indications for Symptom Management, prevention of heart disease, and prevention of osteoporosis. Many trials occurred prior to two pivotal events: the 2002 announcement of the Women's Health Initiative findings and the 2006 publication of the International Patient Decision Aids Standards. Study limitations may help explain contradictory findings for outcomes such as decisional conflict, decisional confidence, decisional satisfaction, knowledge and values, and decisions. Conclusions There is a relatively scant contemporary literature related to menopausal Symptom Management decision aids. Additional methodologically sound studies are needed to develop and subsequently test decision aids that are based on (a) contemporary knowledge regarding the wide array of available therapies and (b) international standards for decision aids that include consideration of women's values and preferences.
Sun Young Rha - One of the best experts on this subject based on the ideXlab platform.
-
Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)—a randomized controlled trial
Supportive Care in Cancer, 2019Co-Authors: Sun Young Rha, Jung Mo Nam, Jiyeon LeeAbstract:PurposeTo develop a Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE) and evaluate the effect and feasibility of the system in cancer Symptom Management.MethodsThe Cancer Symptom Management System: SMILE was developed, and a nonblinded, randomized controlled trial was conducted. Cancer patients starting adjuvant or palliative chemotherapy (CTx) were enrolled and randomized to control (Symptom monitoring), experimental 1 (Exp 1; Symptom monitoring + report), or experimental 2 (Exp 2; Symptom monitoring + report + Oncology Nursing Society putting evidence into practice (ONS PEP)–guided evidence-based Symptom Management education) groups in a 1:2:2 ratio ( N = 249). To evaluate whether Symptom Management education provided additional benefit to continuous Symptom monitoring, the Exp 1 and Exp 2 groups were compared utilizing Mann-Whitney U test and generalized estimating equations ( n = 199).ResultsSymptom severity (Symptom total score) at each measurement point was not different among the three groups ( p > .05). Fatigue and sleep disturbance changes were different between Exp 1 and Exp 2 among patients receiving adjuvant CTx ( p = .042 and p = .008). Fatigue gradually decreased after a peak at the 1st CTx cycle in Exp 2, whereas Exp 1 experienced increasing fatigue until the 3rd CTx cycle. A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the Symptom. Participants were willing to participate in Symptom monitoring using the cancer Symptom Management system. Symptom Management education was easy to follow and helpful.ConclusionThe application of the Cancer Symptom Management System: SMILE incorporating ONS PEP–guided evidence-based Symptom Management education effectively managed fatigue and sleep disturbance after adjuvant CTx. The feasibility of the system has been demonstrated. Incorporating the system into electronic medical systems and integrating provider input will be necessary.
-
Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019Co-Authors: Sun Young Rha, Jung Mo Nam, Jiyeon LeeAbstract:To develop a Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE) and evaluate the effect and feasibility of the system in cancer Symptom Management. The Cancer Symptom Management System: SMILE was developed, and a nonblinded, randomized controlled trial was conducted. Cancer patients starting adjuvant or palliative chemotherapy (CTx) were enrolled and randomized to control (Symptom monitoring), experimental 1 (Exp 1; Symptom monitoring + report), or experimental 2 (Exp 2; Symptom monitoring + report + Oncology Nursing Society putting evidence into practice (ONS PEP)–guided evidence-based Symptom Management education) groups in a 1:2:2 ratio (N = 249). To evaluate whether Symptom Management education provided additional benefit to continuous Symptom monitoring, the Exp 1 and Exp 2 groups were compared utilizing Mann-Whitney U test and generalized estimating equations (n = 199). Symptom severity (Symptom total score) at each measurement point was not different among the three groups (p > .05). Fatigue and sleep disturbance changes were different between Exp 1 and Exp 2 among patients receiving adjuvant CTx (p = .042 and p = .008). Fatigue gradually decreased after a peak at the 1st CTx cycle in Exp 2, whereas Exp 1 experienced increasing fatigue until the 3rd CTx cycle. A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the Symptom. Participants were willing to participate in Symptom monitoring using the cancer Symptom Management system. Symptom Management education was easy to follow and helpful. The application of the Cancer Symptom Management System: SMILE incorporating ONS PEP–guided evidence-based Symptom Management education effectively managed fatigue and sleep disturbance after adjuvant CTx. The feasibility of the system has been demonstrated. Incorporating the system into electronic medical systems and integrating provider input will be necessary.
